GSK Signs Deal to Develop Antibodies for Treating Cancer
GSK GSK entered into an exclusive license agreement with China-based WuXi Biologics (“WuXi Bio”) to develop up to four bi- & multi-specific T-cell engaging (“TCE”) antibodies targeting oncology indications. Per the terms of the agreement, more...
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
The biotech sector was in focus with key pipeline and regulatory updates. Among these, Geron Corporation (GERN) soared on positive study data. Recap of the Week’s Most Important Stories : Geron Surges on Study Results more...
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Biohaven Ltd. (BHVN) one of those stocks right now? Let’s take a closer look at the stock’s more...
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
Moderna MRNA announced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million. The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on more...
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can’t control the latter, but they can focus on a company’s earnings results every quarter. The earnings figure itself is more...
Here’s How Much You’d Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
How much a stock’s price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries more...
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the more...
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
– Machine Learning Model Accelerates Engineering of Polypeptide Therapeutics with Challenging Targets and Mechanisms of Action – BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator more...
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting more...
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that more...